Abstract: Stabilised and aquated polymeric silicate compositions are described in which the compositions are poorly condensed compositions in which the silicates are resorbable and are capable of undergoing efficient dissolution to provide bioavailable soluble silicic acid. In particular, stabilised and aquated polymeric silicates are described that are capable of intravenous delivery, useful in the treatment of cancer or systemic infection, or for topical administration, e.g. in the form of a solid or semi-solid ointment useful in the treatment of wounds or the prevention of bacterial infection.

Abstract: Stabilised and aquated polymeric silicate compositions are described in which the compositions are poorly condensed compositions in which the silicates are resorbable and are capable of undergoing efficient dissolution to provide bioavailable soluble silicic acid. In particular, stabilised and aquated polymeric silicates are described that are capable of intravenous delivery, useful in the treatment of cancer or systemic infection, or for topical administration, e.g. in the form of a solid or semi-solid ointment useful in the treatment of wounds or the prevention of bacterial infection.

Abstract: Processes for recovering colloids of carboxylate ligand modified ferric iron hydroxide materials such as IHAT (Iron Hydroxide Adipate Tartrate) are described based on the use of water miscible non-aqueous solvents, such as ethanol, methanol and acetone. The processes produce materials with advantageous properties such as improved bioavailability, reduced aggregation and/or agglomeration and/or increased iron content.

Abstract: The use of ferric maltol compositions for the treatment or prevention of cancer and tumours is disclosed, in particular for the treatment or prevention of gastrointestinal cancers or gastrointestinal tumours, such as large bowel (colorectal), small bowel or upper gastrointestinal cancers.

Abstract: Methods for producing ferric maltol compositions, such as ferric trimaltol, are described in which maltolis reacted with a ligand modified ferric hydroxide and/or a ligand coated ferric hydroxide.

Abstract: Compositions comprising silica particles having a mean size by standard particle sizing of between 0.5 nm and 20 nm are described for used in activating lymphocytes in culture or in whole blood.

Abstract: Methods for producing ferric maltol compositions, such as ferric trimaltol, from elemental iron, and ferric maltol compositions produced by these methods and their uses are described.

Abstract: Stabilised and aquated polymeric silicate compositions are described in which the compositions are poorly condensed compositions in which the silicates are resorbable and are capable of undergoing efficient dissolution to provide bioavailable soluble silicic acid. In particular, stabilised and aquated polymeric silicates are described that are capable of intravenous delivery, useful in the treatment of cancer or systemic infection, or for topical administration, e.g. in the form of a solid or semi-solid ointment useful in the treatment of wounds or the prevention of bacterial infection.

Abstract: Compositions comprising silica particles having a mean size by standard particle sizing of between 0.5 nm and 20 nm are described for used in activating lymphocytes in culture or in whole blood.

Abstract: Copper based antibacterial agents are described based on amphiphilic copper complexes formed between copper and hydroxypyrones, such as maltol. In further aspects, the present invention relates to PEG based-ointments showing that they are particularly effective for topical delivery of amphiphilic complexes of copper. In particular, PEG ointments were shown to limit bacterial growth, even when in the absence of copper agent. However, this bacteriostatic effect is shown herein to become a true biocidal effect when copper hydroxypyrones are added to the PEG.

Abstract: Stabilised and aquated polymeric silicate compositions are described in which the compositions are poorly condensed compositions in which the silicates are resorbable and are capable of undergoing efficient dissolution to provide bioavailable soluble silicic acid. In particular, stabilised and aquated polymeric silicates are described that are capable of intravenous delivery, useful in the treatment of cancer or systemic infection, or for topical administration, e.g. in the form of a solid or semi-solid ointment useful in the treatment of wounds or the prevention of bacterial infection.

Abstract: The use of ferric maltol compositions for the treatment or prevention of cancer and tumours is disclosed, in particular for the treatment or prevention of gastrointestinal cancers or gastrointestinal tumours, such as large bowel (colorectal), small bowel or upper gastrointestinal cancers.

Abstract: Methods for producing ferric maltol compositions, such as ferric trimaltol, from elemental iron, and ferric maltol compositions produced by these methods and their uses are described.

Abstract: Processes for recovering colloids of carboxylate ligand modified ferric iron hydroxide materials such as IHAT (Iron Hydroxide Adipate Tartrate) are described based on the use of water miscible non-aqueous solvents, such as ethanol, methanol and acetone. The processes produce materials with advantageous properties such as improved bioavailability, reduced aggregation and/or agglomeration and/or increased iron content.

Abstract: Processes for recovering colloids of carboxylate ligand modified ferric iron hydroxide materials such as IHAT (Iron Hydroxide Adipate Tartrate) are described based on the use of water miscible non-aqueous solvents, such as ethanol, methanol and acetone. The processes produce materials with advantageous properties such as improved bioavailability, reduced aggregation and/or agglomeration and/or increased iron content.

Abstract: Amorphous magnesium-substituted calcium, phosphate compositions and their medical uses are described, in particular for use in delivering cargo materials, such as cargo molecules or cargo nanoparticles contained in pores of the amorphous magnesium-substituted calcium phosphate to cells of the immune system, for example as therapeutic approaches for the treatment of inflammatory bowel diseases, and in particular Crohn's disease, autoimmune diseases, allergy and for therapeutic vaccination.

Abstract: Copper based antibacterial agents are described based on amphiphilic copper complexes formed between copper and hydroxypyrones, such as maltol. In further aspects, the present invention relates to PEG based-ointments showing that they are particularly effective for topical delivery of amphiphilic complexes of copper. In particular, PEG ointments were shown to limit bacterial growth, even when in the absence of copper agent. However, this bacteriostatic effect is shown herein to become a true biocidal effect when copper hydroxypyrones are added to the PEG.

Abstract: Methods for producing ferric maltol compositions, such as ferric trimaltol, from ferrous hydroxides, are described, as well as ferric maltol compositions produced by these methods and their uses.

Abstract: Stabilised and aquated polymeric silicate compositions are described in which the compositions are poorly condensed compositions in which the silicates are resorbable and are capable of undergoing efficient dissolution to provide bioavailable soluble silicic acid. In particular, stabilised and aquated polymeric silicates are described that are capable of intravenous delivery, useful in the treatment of cancer or systemic infection, or for topical administration, e.g. in the form of a solid or semi-solid ointment useful in the treatment of wounds or the prevention of bacterial infection.

Abstract: Compositions comprising silica particles having a mean size by standard particle sizing of between 0.5 nm and 20 nm are described for used in activating lymphocytes in culture or in whole blood.